According to a joint media release from Medivation and Astellas Pharma earlier today, the full results of the Phase III AFFIRM trial — of MDV3100 in men with metastatic castration-resistant prostate cancer (mCRPC) who have received docetaxel chemotherapy — will be presented at the ASCO Genitourinary Oncology meeting on February 2, 2012.
This announcement will come as no surprise to experienced prostate cancer watchers. The presentation (“Effect of MDV3100, an androgen receptor signaling inhibitor [ARSI], on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study”) was accepted as a “late-breaking” oral paper and will be given by Dr. Howard Scher, one of the co-principal investigators of the study. The Genitourinary Oncology meeting is being held this year in San Francisco.
We already know that MDV3100 showed a 4.8-month survival benefit compared to a placebo in this trial (according to data released by Medivation last November), but this presentation will give greater insight into side effects and other issues associated with treatment of mCRPC with MDV3100.
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, mCRPC, MDV3100, metastatic |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply